Pharmaceutical intermediates
Niraparib Intermediates
2 pharmaceutical intermediates for Niraparib. Indication: Ovarian Cancer; Peritoneal Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer.
About Niraparib
- Originator
- Tesaro Inc; MSD
- Indication
- Ovarian Cancer; Peritoneal Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer
- Approved Date
- 03/27/2017
- DS/DP
- 08/12/2027
Available intermediates
2 intermediates currently listed for Niraparib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| Methyl 3-formyl-2-nitrobenzoate | 138229-59-1 | / | / |
| (S)-tert-butyl 3-(4-aMinophenyl)piperidine-1-carboxylate | 1171197-20-8 | / | / |
Building toward Niraparib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →